We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > major cardiovascular

News List

Novartis pulls EU filing for canakinumab for the prevention of major cardiovascular events firstwordpharma
December 17, 2018
The European Medicines Agency said Friday that Novartis withdrew a marketing application seeking approval of canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI.
Novartis pulls EU filing for canakinumab for the prevention of major cardiovascular events firstwordpharma
December 17, 2018
The European Medicines Agency said Friday that Novartis withdrew a marketing application seeking approval of canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI.